Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
145.50
+6.50 (4.68%)
At close: Sep 7, 2026

TPEX:7871 Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
113.3450.290.825.7
Revenue Growth
10946.88%6162.39%-96.88%-
Cost of Revenue
0.20.30.642.21
Gross Profit
113.1449.980.1723.48
Selling, General & Admin
71.758.5552.3541.42
Research & Development
261.52187.99164.63103.01
Operating Expenses
333.21246.53216.97144.43
Operating Income
-220.07-196.55-216.81-120.95
Interest Expense
-0.8-0.97-1.31-0.61
Interest & Investment Income
22.2912.117.450.53
Earnings From Equity Investments
---0.31-
Currency Exchange Gain (Loss)
11.554.992.411.92
Other Non Operating Income (Expenses)
21.66-920.78-231.39391.07
EBT Excluding Unusual Items
-165.37-1,101-439.95271.95
Gain (Loss) on Sale of Investments
43.489.67--
Gain (Loss) on Sale of Assets
--0.02-
Other Unusual Items
---0.39-
Pretax Income
-121.89-1,092-440.32271.95
Income Tax Expense
33.9414.97-3.74
Net Income
-155.83-1,107-440.32268.21
Net Income to Common
-155.83-1,107-440.32268.21
Net Income Growth
----
Shares Outstanding (Basic)
133792222
Shares Outstanding (Diluted)
133792280
Shares Change
461.57%256.61%-72.30%-
EPS (Basic)
-1.17-14.02-19.9012.27
EPS (Diluted)
-1.17-14.02-19.903.36
EPS Growth
----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Free Cash Flow
-155.53-132.48-249.67-105.55
Free Cash Flow Per Share
-1.17-1.68-11.28-1.32
Gross Margin
99.83%99.40%20.67%91.38%
Operating Margin
-194.17%-390.85%-26999.63%-470.70%
Profit Margin
-137.48%-2200.37%-54833.75%1043.79%
Free Cash Flow Margin
-137.23%-263.44%-31091.78%-410.76%
EBITDA
-215.13-191.61-213.69-117.9
D&A For EBITDA
4.944.943.123.05
EBIT
-220.07-196.55-216.81-120.95
Effective Tax Rate
---1.38%